These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27125316)

  • 1. Evaluation of ablation of thyroid remnants with 1850 MBq iodine-131 in 67 patients with thyroid cancer.
    Kawabe J; Higashiyama S; Kotani K; Yoshida A; Onoda N; Shiomi S
    Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):68-75. PubMed ID: 27125316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
    Vrachimis A; Schober O; Riemann B
    Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
    Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
    J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
    Cailleux AF; Baudin E; Travagli JP; Ricard M; Schlumberger M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):175-8. PubMed ID: 10634383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
    Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
    Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
    Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
    J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine Uptake and Thyroglobulin-Guided Radioiodine Remnant Ablation in Patients with Differentiated Thyroid Cancer: A Prospective, Randomized, Open-Label, Controlled Trial.
    Jin Y; Ruan M; Cheng L; Fu H; Liu M; Sheng S; Chen L
    Thyroid; 2019 Jan; 29(1):101-110. PubMed ID: 30560716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
    Saengsuda Y
    J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?
    Durante C; Montesano T; Attard M; Torlontano M; Monzani F; Costante G; Meringolo D; Ferdeghini M; Tumino S; Lamartina L; Paciaroni A; Massa M; Giacomelli L; Ronga G; Filetti S;
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2748-53. PubMed ID: 22679061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?
    Piccardo A; Puntoni M; Ferrarazzo G; Foppiani L; Bottoni G; Altrinetti V; Treglia G; Naseri M; Dib B; Cabria M; Trimboli P; Massollo M; Giovanella L
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1218-1223. PubMed ID: 29460027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.
    Robbins RJ; Larson SM; Sinha N; Shaha A; Divgi C; Pentlow KS; Ghossein R; Tuttle RM
    J Nucl Med; 2002 Nov; 43(11):1482-8. PubMed ID: 12411552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
    Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
    Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.
    van der Horst-Schrivers AN; Sluiter WJ; Muller Kobold AC; Wolffenbuttel BH; Plukker JT; Bisschop PH; de Klerk JM; Al Younis I; Lips P; Smit JW; Brouwers AH; Links TP
    PLoS One; 2015; 10(3):e0120184. PubMed ID: 25793762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Success rate of thyroid remnant ablation for differentiated thyroid cancer based on 5550 MBq post-therapy scan.
    Hommel I; Pieters GF; Rijnders AJ; van Borren MM; de Boer H
    Neth J Med; 2016 May; 74(4):152-7. PubMed ID: 27185773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
    Iizuka Y; Katagiri T; Ogura K; Mizowaki T
    Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer.
    Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F
    Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of radioiodine remnant ablation for differentiated thyroid carcinoma patients with an incomplete thyroidectomy.
    Hfu H; Ma C; Li J; Feng F; Wu S; Ye Z; Wang H
    Q J Nucl Med Mol Imaging; 2016 Sep; 60(3):280-4. PubMed ID: 25192307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system.
    Zeuren R; Biagini A; Grewal RK; Randolph GW; Kamani D; Sabra MM; Shaha AR; Tuttle RM
    Laryngoscope; 2015 Oct; 125(10):2417-24. PubMed ID: 25891354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
    Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
    Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.